## Alberto Matteelli

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/52640/publications.pdf

Version: 2024-02-01

222 papers

8,823 citations

50276 46 h-index 85 g-index

225 all docs 225 docs citations

times ranked

225

8674 citing authors

#	Article	IF	CITATIONS
1	Clinical standards for the diagnosis, treatment and prevention of TB infection. International Journal of Tuberculosis and Lung Disease, 2022, 26, 190-205.	1.2	29
2	The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection. International Journal of Infectious Diseases, 2022, 124, S12-S19.	3.3	42
3	Diagnosis and treatment of tuberculosis infection: can it contribute to achieving tuberculosis elimination?. European Respiratory Journal, 2022, 60, 2200540.	6.7	O
4	Healthcare delivery for HIVâ€positive people with tuberculosis in Europe. HIV Medicine, 2021, 22, 283-293.	2.2	6
5	Tuberculosis Preventive Treatment: Key Research Areas and the Clinical Pipeline for New Treatments., 2021,, 415-421.		0
6	Framework for the evaluation of new tests for tuberculosis infection. European Respiratory Journal, 2021, 58, 2004078.	6.7	9
7	Tackling TB in migrants arriving at Europe's southern border. International Journal of Infectious Diseases, 2021, , .	3.3	3
8	TB preventive treatment in high- and intermediate-incidence countries: research needs for scale-up. International Journal of Tuberculosis and Lung Disease, 2021, 25, 823-831.	1.2	8
9	Pulmonary nontuberculous mycobacterial infections and environmental factors: A review of the literature. Respiratory Medicine, 2021, 189, 106660.	2.9	2
10	Severe imported Plasmodium falciparum malaria in children: characteristics and useful factors in the risk stratification. Travel Medicine and Infectious Disease, 2021, 44, 102196.	3.0	0
11	Screening for Tuberculosis in Migrants: A Survey by the Global Tuberculosis Network. Antibiotics, 2021, 10, 1355.	3.7	5
12	Tuberculosis trend among native and foreign-born people over a 17Âyear period (2004–2020) in a large province in Northern Italy. Scientific Reports, 2021, 11, 23394.	3.3	2
13	Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients. BMC Infectious Diseases, 2020, 20, 449.	2.9	2
14	Pharmacokinetics of plasma lopinavir and ritonavir in tuberculosis–HIV co-infected African adult patients also receiving rifabutin 150 or 300Âmg three times per week. Annals of Clinical Microbiology and Antimicrobials, 2020, 19, 3.	3.8	3
15	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. International Journal of Infectious Diseases, 2020, 92, S15-S25.	3.3	126
16	Guidance for programmatic management of latent tuberculosis infection in the European Union/European Economic Area. European Respiratory Journal, 2019, 53, 1802077.	6.7	28
17	Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. International Journal of Infectious Diseases, 2019, 83, 72-76.	3.3	41
18	Building a European database to gather multi-country evidence on active and latent TB screening for migrants. International Journal of Infectious Diseases, 2019, 80, S45-S49.	3.3	9

#	Article	IF	Citations
19	Global tuberculosis prevention: should we start from the beginning?. European Respiratory Journal, 2019, 54, 1901394.	6.7	9
20	The Traveler With HIV. , 2019, , 279-286.		0
21	Screening for active and latent tuberculosis among asylum seekers in Italy: A retrospective cohort analysis. Travel Medicine and Infectious Disease, 2019, 27, 39-45.	3.0	22
22	Incident genital HPV infections and potential impact of HPV vaccines in adult women living with HIV/AIDS. Human Vaccines and Immunotherapeutics, 2019, 15, 1904-1910.	3.3	3
23	Business travel-associated illness: a GeoSentinel analysisâ€. Journal of Travel Medicine, 2018, 25, .	3.0	42
24	Xpert MTB/RIF as add-on test to microscopy in a low tuberculosis incidence setting. European Respiratory Journal, 2018, 51, 1702345.	6.7	5
25	Imported malaria in northern Italy: epidemiology and clinical features observed over 18 years in the Teaching Hospital of Brescia. Journal of Travel Medicine, 2018, 25, .	3.0	12
26	Tuberculosis elimination: a dream or a reality? The case of Oman. European Respiratory Journal, 2018, 51, 1702027.	6.7	18
27	Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study. Journal of Infection, 2018, 76, 44-54.	3.3	16
28	Antiretroviral Therapy in HIV-Infected Children With Tuberculosis. Pediatric Infectious Disease Journal, 2018, 37, e117-e125.	2.0	7
29	Implementation of tuberculosis prevention for exposed children, Burkina Faso. Bulletin of the World Health Organization, 2018, 96, 386-392.	3.3	4
30	Towards tackling tuberculosis in vulnerable groups in the European Union: the E-DETECT TB consortium. European Respiratory Journal, 2018, 51, 1702604.	6.7	15
31	Defining a migrant-inclusive tuberculosis research agenda to end TB. International Journal of Tuberculosis and Lung Disease, 2018, 22, 835-843.	1.2	14
32	An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease. European Respiratory Journal, 2018, 52, 1800946.	6.7	27
33	Tuberculosis elimination: where are we now?. European Respiratory Review, 2018, 27, 180035.	7.1	76
34	The effectiveness and cost-effectiveness of screening for active tuberculosis among migrants in the EU/EEA: a systematic review. Eurosurveillance, 2018, 23, .	7.0	31
35	The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review. Eurosurveillance, 2018, 23, .	7.0	25
36	Tuberculosis elimination and the challenge of latent tuberculosis. Presse Medicale, 2017, 46, e13-e21.	1.9	48

#	Article	IF	CITATIONS
37	Breaking the barriers: Migrants and tuberculosis. Presse Medicale, 2017, 46, e5-e11.	1.9	26
38	Louse-borne relapsing fever in a refugee from Mali. Infection, 2017, 45, 373-376.	4.7	9
39	Moving towards tuberculosis elimination: a call for action from Italy and a possible model for other low tuberculosis incidence countries. European Respiratory Journal, 2017, 49, 1602242.	6.7	11
40	Genetic Resistance Determinants for Cefixime and Molecular Analysis of Gonococci Isolated in Italy. Microbial Drug Resistance, 2017, 23, 247-252.	2.0	6
41	Tuberculosis-a World Health Organization Perspective. , 2017, , 211-228.		2
42	Socioeconomic status and biomedical risk factors in migrants and native tuberculosis patients in Italy. PLoS ONE, 2017, 12, e0189425.	2.5	6
43	Tailoring Treatment of Latent Tuberculosis to the Needs of Patients and Families. Annals of Internal Medicine, 2017, 167, 742.	3.9	2
44	Time trend analysis (2009-2016) of antimicrobial susceptibility in Neisseria gonorrhoeae isolated in Italy following the introduction of the combined antimicrobial therapy. PLoS ONE, 2017, 12, e0189484.	2.5	9
45	Sentinel surveillance of imported dengue via travellers to Europe 2012 to 2014: TropNet data from the DengueTools Research Initiative. Eurosurveillance, 2017, 22, .	7.0	46
46	A strange case of Malaria in a Nigerian native boy Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017023.	1.3	2
47	New Antituberculosis Drugs: From Clinical Trial to Programmatic Use. Gastroenterology Insights, 2016, 8, 6569.	1.2	53
48	Policies and practices on the programmatic management of latent tuberculous infection: global survey. International Journal of Tuberculosis and Lung Disease, 2016, 20, 1566-1571.	1.2	13
49	Continuous isoniazid for the treatment of latent tuberculosis infection in people living with HIV. Aids, 2016, 30, 797-801.	2.2	37
50	Crossborder travel and multidrugresistant tuberculosis (MDRTB) in Europe. Travel Medicine and Infectious Disease, 2016, 14, 588-590.	3.0	9
51	Comparison of effectiveness and safety of imipenem/clavulanate-containing regimens in the treatment of MDR-ÂandÂXDR-TB. European Respiratory Journal, 2016, 47, 1758-1766.	6.7	69
52	Advancing global programmatic management of latent tuberculosis infection for at risk populations. European Respiratory Journal, 2016, 47, 1327-1330.	6.7	22
53	The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2016, 16, 1269-1278.	9.1	334
54	Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis. International Journal of Tuberculosis and Lung Disease, 2016, 20, 1065-1071.	1.2	33

#	Article	IF	CITATIONS
55	Recent developments in the diagnosis and management of tuberculosis. Npj Primary Care Respiratory Medicine, 2016, 26, 16078.	2.6	58
56	The Holy Grail of prevention of sexually transmitted infections in travellers. Sexually Transmitted Infections, 2016, 92, 405-406.	1.9	9
57	WHO strategies for the programmatic management of drug-resistant tuberculosis. Expert Review of Respiratory Medicine, 2016, 10, 991-1002.	2.5	34
58	Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. European Respiratory Journal, 2016, 48, 938-943.	6.7	71
59	Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection in adolescents in Northern Italy: an observational school-based study. BMC Public Health, 2016, 16, 200.	2.9	6
60	Recommendations for treating children with drug-resistant tuberculosis. Pharmacological Research, 2016, 105, 176-182.	7.1	17
61	Cameroon's multidrug-resistant tuberculosis treatment programme jeopardised by cross-border migration. European Respiratory Journal, 2016, 47, 686-688.	6.7	17
62	Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Clinical Infectious Diseases, 2016, 62, 1188.2-1190.	5.8	34
63	Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. European Respiratory Journal, 2016, 47, 1235-1243.	6.7	92
64	A scoping review of cost-effectiveness of screening and treatment for latent tuberculosis infection in migrants from high-incidence countries. BMC Health Services Research, 2015, 15, 412.	2.2	53
65	Latent tuberculous infection: ethical considerations in formulating public health policy. International Journal of Tuberculosis and Lung Disease, 2015, 19, 137-140.	1.2	19
66	In reply. Promoting ethical and evidence-based policies for latent tuberculosis. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1258-1259.	1.2	1
67	Identification of the skin virome in a boy with widespread human papillomavirusâ€2â€positive warts that completely regressed after administration of tetravalent human papillomavirus vaccine. British Journal of Dermatology, 2015, 173, 597-600.	1.5	9
68	Major differences in organization and availability of health care and medicines for <scp>HIV/TB</scp> coinfected patients across <scp>E</scp> urope. HIV Medicine, 2015, 16, 544-552.	2.2	19
69	Mycobacterium sherrisiiPulmonary Disease, Burkina Faso. Emerging Infectious Diseases, 2015, 21, 2093-2094.	4.3	3
70	Chlamydia trachomatis genotypes in school adolescents, Italy. Infection, 2015, 43, 739-741.	4.7	1
71	Latent <i>Mycobacterium tuberculosis</i> li>Infection. New England Journal of Medicine, 2015, 372, 2127-2135.	27.0	578
72	Diabetes and tuberculosis: what else beyond?. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1127-1128.	1.2	4

#	Article	IF	Citations
73	Numbers needed to treat to prevent tuberculosis. European Respiratory Journal, 2015, 46, 1838-1839.	6.7	9
74	The impact of Xpert® MTB/RIF depends on service coordination: experience in Burkina Faso. International Journal of Tuberculosis and Lung Disease, 2015, 19, 285-287.	1.2	8
75	Exogenous reinfection of tuberculosis in a low-burden area. Infection, 2015, 43, 647-653.	4.7	25
76	Towards tuberculosis elimination: an action framework for low-incidence countries. European Respiratory Journal, 2015, 45, 928-952.	6.7	608
77	Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review <i>versus</i> expert opinion. European Respiratory Journal, 2015, 45, 1170-1173.	6.7	15
78	Management of latent <i>Mycobacterium tuberculosis</i> infection: WHO guidelines for low tuberculosis burden countries. European Respiratory Journal, 2015, 46, 1563-1576.	6.7	475
79	Differences in BCG vaccination and tuberculin skin-test positivity. Lancet Infectious Diseases, The, 2015, 15, 1003.	9.1	4
80	Compassionate and optimum use of new tuberculosis drugs. Lancet Infectious Diseases, The, 2015, 15, 1131-1132.	9.1	32
81	Regional Variation in Travel-related Illness acquired in Africa, March 1997–May 2011. Emerging Infectious Diseases, 2014, 20, 532-541.	4.3	37
82	TUBERCULOSIS: EPIDEMIOLOGY AND CONTROL. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014070.	1.3	116
83	Risk of cervical HPV infection and prevalence of vaccine-type and other high-risk HPV types among sexually active teens and young women (13–26 years) enrolled in the VALHIDATE study. Human Vaccines and Immunotherapeutics, 2014, 10, 986-994.	3.3	15
84	Recrudescence of <i>Plasmodium falciparum </i> malaria in a primigravid woman with anaemia as the only sign of disease. Journal of Obstetrics and Gynaecology, 2014, 34, 356-356.	0.9	5
85	Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. European Respiratory Journal, 2014, 44, 23-63.	6.7	256
86	ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. European Respiratory Journal, 2014, 44, 811-815.	6.7	96
87	New Italian guidelines for malaria prophylaxis in travellers to endemic areas. Infection, 2014, 42, 239-250.	4.7	11
88	Imported Plasmodium vivax Malaria ex Pakistan. Journal of Travel Medicine, 2014, 21, 314-317.	3.0	10
89	Screening for Chlamydia trachomatis and Neisseria gonorrhoeae among high-school participants using the Versant CT/GC DNA 1.0 assay (kinetic PCR). Journal of Medical Microbiology, 2014, 63, 1237-1239.	1.8	1
90	Risk Assessment of Tuberculosis in Immunocompromised Patients. A TBNET Study. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1168-1176.	5.6	196

#	Article	IF	CITATIONS
91	Changing Antimicrobial Resistance Profiles among Neisseria gonorrhoeae Isolates in Italy, 2003 to 2012. Antimicrobial Agents and Chemotherapy, 2014, 58, 5871-5876.	3.2	16
92	Treatment Optimization in Patients Co-Infected with HIV and Mycobacterium tuberculosis Infections: Focus on Drug–Drug Interactions with Rifamycins. Clinical Pharmacokinetics, 2014, 53, 489-507.	<b>3.</b> 5	62
93	Travel, syphilis and HIV. Travel Medicine and Infectious Disease, 2014, 12, 5-6.	3.0	3
94	Extensively drug-resistant tuberculosis: epidemiology and management. Clinical Epidemiology, 2014, 6, 111.	3.0	98
95	Chlamydia trachomatis conjunctivitis in a male teenager: a case report. Infezioni in Medicina, 2014, 22, 140-3.	1.1	3
96	Contact investigation based on serial interferon-gamma release assays (IGRA) in children from the hematology-oncology ward after exposure to a patient with pulmonary tuberculosis. Infection, 2013, 41, 827-831.	4.7	16
97	Disseminated Mycobacterium genavense infection after immunosuppressive therapy shows underlying new composite heterozygous mutations of $\hat{l}^21$ subunit of IL-12 receptor gene. Journal of Allergy and Clinical Immunology, 2013, 131, 607-610.	2.9	8
98	Travel-associated sexually transmitted infections: an observational cross-sectional study of the GeoSentinel surveillance database. Lancet Infectious Diseases, The, 2013, 13, 205-213.	9.1	69
99	Acute HIV infection at travel clinics – Authors' reply. Lancet Infectious Diseases, The, 2013, 13, 651-652.	9.1	0
100	Indicator condition-guided HIV testing in Europe: a step forward to HIV control:. European Respiratory Journal, 2013, 42, 572-575.	6.7	3
101	Tuberculosis: are we making it incurable?. European Respiratory Journal, 2013, 42, 5-8.	6.7	17
102	Drug-resistant tuberculosis. Current Opinion in Pulmonary Medicine, 2013, 19, 266-272.	2.6	42
103	Respiratory Infections., 2013,, 511-522.		1
104	miRNA Signatures in Sera of Patients with Active Pulmonary Tuberculosis. PLoS ONE, 2013, 8, e80149.	2.5	70
105	Multidrug-resistant tuberculosis today. Bulletin of the World Health Organization, 2012, 90, 78-78.	3.3	19
106	ADVANCES IN THE TREATMENT OF MALARIA. Mediterranean Journal of Hematology and Infectious Diseases, 2012, 4, e2012064.	1.3	7
107	Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. Journal of Antimicrobial Chemotherapy, 2012, 67, 2470-2473.	3.0	10
108	Early tuberculosis treatment monitoring by Xpert® MTB/RIF: Figure 1–. European Respiratory Journal, 2012, 39, 1269-1271.	6.7	61

#	Article	IF	Citations
109	Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso. Journal of Antimicrobial Chemotherapy, 2012, 67, 469-472.	3.0	11
110	Impact of Previous ART and of ART Initiation on Outcome of HIV-Associated Tuberculosis. Clinical and Developmental Immunology, 2012, 2012, 1-8.	3.3	15
111	Cervical Human Papillomavirus Infection and Shedding of Human Immunodeficiency Virus in Cervicovaginal Fluids. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 78-82.	2.1	3
112	Visiting Relatives and Friends (VFR), Pregnant, and Other Vulnerable Travelers. Infectious Disease Clinics of North America, 2012, 26, 625-635.	5.1	19
113	Cefixime and ceftriaxone susceptibility of Neisseria gonorrhoeae in Italy from 2006 to 2010. Clinical Microbiology and Infection, 2012, 18, 558-564.	6.0	15
114	Update on antimicrobial susceptibility and genotype of Neisseria gonorrhoeae isolated in Italy. Diagnostic Microbiology and Infectious Disease, 2012, 72, 288-290.	1.8	4
115	Rationale and design of a multicenter prospective cohort study for the eVALuation and monitoring of HPV infections and relATEd cervical diseases in high-risk women (VALHIDATE study). BMC Cancer, 2012, 12, 204.	2.6	5
116	Rediscovering high technology from the past: thoracic surgery is back on track for multidrug-resistant tuberculosis. Expert Review of Anti-Infective Therapy, 2012, 10, 1109-1115.	4.4	11
117	Therapy of uncomplicated falciparum malaria in Europe: MALTHER – a prospective observational multicentre study. Malaria Journal, 2012, 11, 212.	2.3	30
118	Treatment of TB. , 2012, , 154-166.		9
119	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiologica, 2012, 35, 113-59.	0.1	25
120	Delayed Diagnosis of Disseminated Mycobacterium genavense Infection in a Human Immunodeficiency Virus-Negative Young Woman. Infectious Diseases in Clinical Practice, 2011, 19, 286-287.	0.3	0
121	Continuous monitoring of implemented tuberculosis control measures in middle-income high-endemic countries. Journal of Hospital Infection, 2011, 77, 178-179.	2.9	1
122	A comparative examination of tuberculosis immigration medical screening programs from selected countries with high immigration and low tuberculosis incidence rates. BMC Infectious Diseases, 2011, 11, 3.	2.9	66
123	Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is "blind" treatment dangerous?. European Respiratory Journal, 2011, 37, 1283-1285.	6.7	14
124	Tuberculosis and HIV co-infection: do we have a surveillance system in Europe?: Table 1–. European Respiratory Journal, 2011, 38, 1258-1260.	6.7	10
125	Differential Diagnosis of Cervical Mycobacterial Lymphadenitis in Children. Pediatric Infectious Disease Journal, 2010, 29, 629-633.	2.0	27
126	Genotyping analyses of tuberculosis transmission among immigrant residents in Italy. Clinical Microbiology and Infection, 2010, 16, 1149-1154.	6.0	22

#	Article	IF	CITATIONS
127	Travel Case Scenarios as a Demonstration of Risk Assessment of VFR Travelers: Introduction to Criteria and Evidenceâ€Based Definition and Framework: Table 1. Journal of Travel Medicine, 2010, 17, 153-162.	3.0	22
128	The Visiting Friends or Relatives Traveler in the 21st Century: Time for a New Definition. Journal of Travel Medicine, 2010, 17, 163-170.	3.0	78
129	Is a new definition required for travelers who visit friends and relatives?. Journal of Travel Medicine, 2010, 17, 430-431.	3.0	4
130	Methicillin-ResistantStaphylococcus aureusST398, Italy. Emerging Infectious Diseases, 2010, 16, 346-348.	4.3	35
131	Extensively Drug-Resistant Tuberculosis, Burkina Faso. Emerging Infectious Diseases, 2010, 16, 840-842.	4.3	14
132	TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiology, 2010, 5, 849-858.	2.0	158
133	Trend of ciprofloxacin resistance in Neisseria gonorrhoeae strains isolated in Italy and analysis of the molecular determinants. Diagnostic Microbiology and Infectious Disease, 2010, 67, 350-354.	1.8	10
134	Congenital Plasmodium vivax malaria mimicking neonatal sepsis: a case report. Malaria Journal, 2010, 9, 63.	2.3	29
135	Multidrug- and extensively drug-resistant TB in persons living with HIV. Expert Review of Respiratory Medicine, 2009, 3, 245-254.	2.5	8
136	Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy, 2009, 64, 879-883.	3.0	10
137	Women Facing HIV. Key Question on Women with HIV Infection: Italian Consensus Workshop. Infection, 2009, 37, 168-178.	4.7	5
138	Molecular detection of rifampin and isoniazid resistance to guide chronic TB patient management in Burkina Faso. BMC Infectious Diseases, 2009, 9, 142.	2.9	21
139	Epidemiological phenotypic characteristics of vaginal yeasts at the Comoros. Mycoses, 2009, 52, 458-461.	4.0	3
140	Corrigendum. Expert Review of Respiratory Medicine, 2009, 3, 447-448.	2.5	0
141	Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. European Respiratory Journal, 2009, 33, 871-881.	6.7	163
142	Reversible Reduction of Nevirapine Plasma Concentrations During Rifampicin Treatment in Patients Coinfected With HIV-1 and Tuberculosis. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 64-69.	2.1	16
143	Recent Acquired STD and the Use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): Analysis of the Incidence of Newly Acquired Hepatitis B Infection and Syphilis. Infection, 2008, 36, 46-53.	4.7	10
144	Acute Renal Failure Due to Visceral Leishmaniasis byLeishmania infantumSuccessfully Treated With a Single High Dose of Liposomal Amphotericin B. Journal of Travel Medicine, 2008, 15, 358-360.	3.0	16

#	Article	IF	CITATIONS
145	Phenotypic and genotypic characterization of Neisseria gonorrhoeae in parts of Italy: detection of a multiresistant cluster circulating in a heterosexual network. Clinical Microbiology and Infection, 2008, 14, 949-954.	6.0	18
146	AUTHORS' CORRIGENDUM. Clinical Microbiology and Infection, 2008, 14, 1087.	6.0	4
147	QuantiFERON®-TB Gold test for healthcare workers. Journal of Hospital Infection, 2008, 69, 91-92.	2.9	6
148	Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. European Respiratory Journal, 2008, 31, 1155-1159.	6.7	131
149	High incidence of sputum smear negative tuberculosis during HAART in Burkina Faso. European Respiratory Journal, 2008, 32, 1668-1669.	6.7	4
150	Extensively Drug-Resistant Tuberculosis Is Worse than Multidrug-Resistant Tuberculosis: Different Methodology and Settings, Same Results. Clinical Infectious Diseases, 2008, 46, 958-959.	5.8	35
151	Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis?. European Respiratory Journal, 2008, 31, 904-905.	6.7	67
152	Treatment patterns and associated costs for genital warts in Italy. Current Medical Research and Opinion, 2008, 24, 3175-3183.	1.9	17
153	Tuberculosis, one disease, many faces. Monaldi Archives for Chest Disease, 2008, 69, 2-4.	0.6	7
154	Diagnosis of Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis: Current Standards and Challenges. Canadian Journal of Infectious Diseases and Medical Microbiology, 2008, 19, 169-172.	1.9	56
155	Respiratory Diseases. , 2008, , 561-572.		1
156	Clinical and operational value of the extensively drug-resistant tuberculosis definition. European Respiratory Journal, 2007, 30, 623-626.	6.7	179
157	Fatal Disseminated Toxoplasmosis During Primary HIV Infection. Current HIV Research, 2007, 5, 273-274.	0.5	13
158	Multiple-Dose Pharmacokinetics of Efavirenz with and without the Use of Rifampicin in HIV-Positive Patients. Current HIV Research, 2007, 5, 349-353.	0.5	50
159	Ripped from the headlines: how can we harness communications to control TB?. European Respiratory Journal, 2007, 30, 194-198.	6.7	7
160	Congenital syphilis in Italy. Sexually Transmitted Infections, 2007, 83, 590-591.	1.9	9
161	Antimicrobial prevention and therapy for travelers' infection. Expert Review of Anti-Infective Therapy, 2007, 5, 1031-1048.	4.4	2
162	Multidrug-resistant and extensively drug-resistant <i>Mycobacterium tuberculosis</i> : epidemiology and control. Expert Review of Anti-Infective Therapy, 2007, 5, 857-871.	4.4	101

#	Article	IF	CITATIONS
163	QuantiFERON®-TB Gold test in the identification of latent tuberculosis infection in immigrants. Journal of Infection, 2007, 55, 164-168.	3.3	37
164	Prevalence and Incidence of Syphilis Among South American Transgender Sex Workers in Northern Italy. Sexually Transmitted Diseases, 2006, 33, 334-335.	1.7	9
165	Acute Respiratory Distress Syndrome inPlasmodium vivaxMalaria in Traveler Returning From Venezuela. Journal of Travel Medicine, 2006, 13, 112-113.	3.0	31
166	Prevalence of pfcrt point mutations and level of chloroquine resistance in Plasmodium falciparum isolates from Africa. Infection, Genetics and Evolution, 2006, 6, 262-268.	2.3	27
167	Nodular Lesion of the Skin as Primary Cutaneous Tuberculosis. Journal of Travel Medicine, 2006, 10, 306-308.	3.0	4
168	Imported Malaria in an HIV-Positive Traveler: A Case Report with a Fatal Outcome. Journal of Travel Medicine, 2006, 12, 222-224.	3.0	6
169	Inappropriate Footwear and Rat-Bite Fever in an International Traveler. Journal of Travel Medicine, 2006, 9, 275-276.	3.0	7
170	Vaginal colonization with Candida spp. in human immunodeficiency virus – infected women: a cohort study. International Journal of STD and AIDS, 2006, 17, 260-266.	1.1	23
171	Paradoxical Reaction during Tuberculosis Treatment in HIV-Seronegative Patients. Clinical Infectious Diseases, 2006, 42, 893-895.	<b>5.</b> 8	42
172	Completion of screening for latent tuberculosis infection among immigrants. Epidemiology and Infection, 2005, 133, 179-185.	2.1	25
173	Mefloquine versus Quinine plus Sulphalene-Pyrimethamine (Metakelfin) for Treatment of Uncomplicated Imported Falciparum Malaria Acquired in Africa. Antimicrobial Agents and Chemotherapy, 2005, 49, 663-667.	3.2	16
174	Respiratory Syndrome and Respiratory Tract Infections in Foreign-Born and National Travelers Hospitalized with Fever in Italy. Journal of Travel Medicine, 2005, 12, 190-196.	3.0	8
175	Screening for Mutations Related to Atovaquone/Proguanil Resistance in Treatment Failures and Other Imported Isolates ofPlasmodium falciparumin Europe. Journal of Infectious Diseases, 2004, 190, 1541-1546.	4.0	73
176	Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy. European Respiratory Journal, 2004, 24, 11-17.	6.7	53
177	Prevalence of Anti-poliovirus Type 1, 2 and 3 Antibodies in Unvaccinated Italian Travelers. Journal of Travel Medicine, 2004, 11, 34-36.	3.0	3
178	Epidemiology and clinical features of vivax malaria imported to Europe: sentinel surveillance data from TropNetEurop. Malaria Journal, 2004, 3, 5.	2.3	79
179	An epidemiological survey of vulvovaginal candidiasis in Italy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2003, 110, 66-72.	1.1	135
180	Molecular surveillance of the antifolate-resistant mutation I164L in imported African isolates of Plasmodium falciparum in Europe: sentinel data from TropNetEurop. Malaria Journal, 2003, 2, 17.	2.3	18

#	Article	IF	CITATIONS
181	Chlamydia trachomatis genital infection in migrant female sex workers in Italy. International Journal of STD and AIDS, 2003, 14, 591-595.	1.1	22
182	Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998–2000. European Respiratory Journal, 2003, 21, 129-134.	6.7	12
183	Age as a Risk Factor for Severe Manifestations and Fatal Outcome of Falciparum Malaria in European Patients: Observations from TropNetEurop and SIMPID Surveillance Data. Clinical Infectious Diseases, 2003, 36, 990-995.	5.8	93
184	Malaria Clusters among Illegal Chinese Immigrants to Europe through Africa. Emerging Infectious Diseases, 2003, 9, 1177-1178.	4.3	10
185	Imported Schistosomiasis in Europe: Sentinel Surveillance Data from TropNetEurop. Journal of Travel Medicine, 2003, 10, 164-167.	3.0	72
186	gammadelta T lymphocytes in the peripheral blood of patients with tuberculosis with and without HIV co-infection. Thorax, 2002, 57, 357-360.	5.6	19
187	Role of Th1 and Th2 Cytokines in Immune Response to Uncomplicated Plasmodium falciparum Malaria. Vaccine Journal, 2002, 9, 348-351.	3.1	62
188	Imported Falciparum Malaria in Europe: Sentinel Surveillance Data from the European Network on Surveillance of Imported Infectious Diseases. Clinical Infectious Diseases, 2002, 34, 572-576.	5.8	228
189	STI epidemics in the Indian Ocean region: can the phase be assessed?. Sexually Transmitted Infections, 2002, 78, i121-i124.	1.9	4
190	Epidemiology and Clinical Features of Imported Dengue Fever in Europe: Sentinel Surveillance Data from TropNetEurop. Clinical Infectious Diseases, 2002, 35, 1047-1052.	5.8	160
191	High prevalence of a variant of SENV in intravenous drug user HIVâ€infected patients. Journal of Medical Virology, 2002, 68, 18-23.	5.0	15
192	Knowledge, Attitudes, and Practices on Malaria Preventive Measures of Migrants Attending a Public Health Clinic in Northern Italy. Journal of Travel Medicine, 2002, 9, 160-162.	3.0	42
193	Sexually Transmitted Diseases in Travelers. Clinical Infectious Diseases, 2001, 32, 1063-1067.	5.8	100
194	Efficacy and Tolerability of Topical 1% Cidofovir Cream for the Treatment of External Anogenital Warts in HIV-Infected Persons. Sexually Transmitted Diseases, 2001, 28, 343-346.	1.7	34
195	Molecular Epidemiology Study of Exogenous Reinfection in an Area with a Low Incidence of Tuberculosis. Journal of Clinical Microbiology, 2001, 39, 2213-2218.	3.9	123
196	Prevalence and risk factors of HSV-1 and HSV-2 antibodies in European HIV infected women. Sexually Transmitted Infections, 2001, 77, 120-124.	1.9	26
197	Malaria in Illegal Chinese Immigrants, Italy. Emerging Infectious Diseases, 2001, 7, 1055-1058.	4.3	22
198	Serum levels of interleukin-18 in patients with uncomplicated Plasmodium falciparum malaria. European Cytokine Network, 2001, 12, 361-4.	2.0	18

#	Article	IF	CITATIONS
199	Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. Aids, 2000, 14, 1985-1991.	2.2	139
200	Prevalence and distribution of soil-transmitted helminth (STH) infections in urban and indigenous schoolchildren in Ortigueira, State of Parana, Brasil: implications for control. Tropical Medicine and International Health, 2000, 5, 302-307.	2.3	50
201	Supervised Preventive Therapy for Latent Tuberculosis Infection in Illegal Immigrants in Italy. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 1653-1655.	5.6	35
202	Passive sentinel surveillance system for sexually transmitted diseases in primary healthcare sites in Ethiopia, 1991-3. Sexually Transmitted Infections, 2000, 76, 131-133.	1.9	6
203	Epidemiological features and case management practices of imported malaria in northern Italy 1991-1995. Tropical Medicine and International Health, 1999, 4, 653-657.	2.3	48
204	Pediatric Migration and Hepatitis A Risk in Host Population. Journal of Travel Medicine, 1999, 6, 204-206.	3.0	18
205	Neurocysticercosis in an Italian traveler to Latin America American Journal of Tropical Medicine and Hygiene, 1999, 60, 255-256.	1.4	18
206	Short report: Diagnosis of tick-borne relapsing fever by the quantitative buffy coat fluorescence method American Journal of Tropical Medicine and Hygiene, 1999, 60, 738-739.	1.4	21
207	Incidence of tuberculosis in a community of Senegalese immigrants in Northern Italy. International Journal of Tuberculosis and Lung Disease, 1999, 3, 18-22.	1.2	7
208	Malaria in migrants. Parassitologia, 1999, 41, 261-5.	0.5	22
209	Levels of circulating nitrate/nitrite and gamma interferon not increased in uncomplicated malaria. Infection, 1998, 26, 301-303.	4.7	8
210	Long Term Treatment with Clarithromycin for Cryptosporidiosis and Emergence of Drug Resistant Disseminated Infection Due to <i>Mycobacterium avium:</i> Case Report. Journal of Chemotherapy, 1998, 10, 474-475.	1.5	2
211	The placenta and malaria. Annals of Tropical Medicine and Parasitology, 1997, 91, 803-810.	1.6	61
212	The placenta and malaria. Annals of Tropical Medicine and Parasitology, 1997, 91, 803-810.	1.6	23
213	Malaric Placentas. Pathology Research and Practice, 1996, 192, 892-898.	2.3	58
214	Malarial infection and birthweight in urban Zanzibar, Tanzania. Annals of Tropical Medicine and Parasitology, 1996, 90, 125-134.	1.6	28
215	Prophylaxis for Tuberculosis in Europe—Ongoing Research. Clinical Infectious Diseases, 1996, 22, S55-S60.	5.8	6
216	Short Report: Primaquine-Tolerant Plasmodium vivax in an Italian Traveler from Guatemala. American Journal of Tropical Medicine and Hygiene, 1996, 55, 472-473.	1.4	13

#	ARTICLE	IF	CITATIONS
217	Failure of Mefloquine Chemoprophylaxis for Malaria in Mozambique. Journal of Travel Medicine, 1995, 2, 260-261.	3.0	5
218	Insecticide-impregnated bed nets reduce malaria transmission in rural Zanzibar. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88, 150-154.	1.8	31
219	Malaria and anaemia in pregnant women in urban Zanzibar, Tanzania. Annals of Tropical Medicine and Parasitology, 1994, 88, 475-483.	1.6	74
220	Short Report: Verruga Peruana in an Italian Traveler from Peru. American Journal of Tropical Medicine and Hygiene, 1994, 50, 143-144.	1.4	28
221	â€~Baggage malaria' in Italy: cryptic malaria explained?. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87, 394.	1.8	33
222	Reversal of chloroquine resistance of â€~wild' isolates of Plasmodium falciparum by desipramine. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1991, 85, 723-724.	1.8	8